777 related articles for article (PubMed ID: 31080168)
1. Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study.
Garweg JG; Stefanickova J; Hoyng C; Schmelter T; Niesen T; Sowade O; Sivaprasad S;
Ophthalmol Retina; 2019 Jul; 3(7):567-575. PubMed ID: 31080168
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal aflibercept for diabetic macular edema.
Korobelnik JF; Do DV; Schmidt-Erfurth U; Boyer DS; Holz FG; Heier JS; Midena E; Kaiser PK; Terasaki H; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Brown DM
Ophthalmology; 2014 Nov; 121(11):2247-54. PubMed ID: 25012934
[TBL] [Abstract][Full Text] [Related]
3. Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration.
Yuzawa M; Fujita K; Wittrup-Jensen KU; Norenberg C; Zeitz O; Adachi K; Wang EC; Heier J; Kaiser P; Chong V; Korobelnik JF
Ophthalmology; 2015 Mar; 122(3):571-8. PubMed ID: 25439429
[TBL] [Abstract][Full Text] [Related]
4. [New perspectives in the approach to diabetic macular edema. Aflibercept therapy].
Ruiz-Moreno JM
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():24-8. PubMed ID: 25925048
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF
Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808
[TBL] [Abstract][Full Text] [Related]
6. Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration.
Zhu M; Wijeyakumar W; Syed AR; Joachim N; Hong T; Broadhead GK; Li H; Luo K; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):475-484. PubMed ID: 27572301
[TBL] [Abstract][Full Text] [Related]
7. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY; Haskova Z; Asik K; Baumal CR; Csaky KG; Eter N; Ives JA; Jaffe GJ; Korobelnik JF; Lin H; Murata T; Ruamviboonsuk P; Schlottmann PG; Seres AI; Silverman D; Sun X; Tang Y; Wells JA; Yoon YH; Wykoff CC;
Ophthalmology; 2024 Jun; 131(6):708-723. PubMed ID: 38158159
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.
Campochiaro PA; Clark WL; Boyer DS; Heier JS; Brown DM; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Haller JA
Ophthalmology; 2015 Mar; 122(3):538-44. PubMed ID: 25315663
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.
Brown DM; Heier JS; Clark WL; Boyer DS; Vitti R; Berliner AJ; Zeitz O; Sandbrink R; Zhu X; Haller JA
Am J Ophthalmol; 2013 Mar; 155(3):429-437.e7. PubMed ID: 23218699
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal aflibercept for diabetic macular oedema: Moorfields' real-world 12-month visual acuity and anatomical outcomes.
Lukic M; Williams G; Shalchi Z; Sim D; Patel PJ; Keane PA; Hykin PG; Sivaprasad S; Menon D; Bruynseels A; Hamilton RD; Rajendram R
Eur J Ophthalmol; 2020 May; 30(3):557-562. PubMed ID: 30808179
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial.
Glassman AR; Baker CW; Beaulieu WT; Bressler NM; Punjabi OS; Stockdale CR; Wykoff CC; Jampol LM; Sun JK;
JAMA Ophthalmol; 2020 Apr; 138(4):341-349. PubMed ID: 32077907
[TBL] [Abstract][Full Text] [Related]
12. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.
Mitchell P; Bandello F; Schmidt-Erfurth U; Lang GE; Massin P; Schlingemann RO; Sutter F; Simader C; Burian G; Gerstner O; Weichselberger A;
Ophthalmology; 2011 Apr; 118(4):615-25. PubMed ID: 21459215
[TBL] [Abstract][Full Text] [Related]
13. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.
Clark WL; Boyer DS; Heier JS; Brown DM; Haller JA; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Campochiaro PA
Ophthalmology; 2016 Feb; 123(2):330-336. PubMed ID: 26522708
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes.
Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R
Eur J Ophthalmol; 2021 May; 31(3):1201-1207. PubMed ID: 32429690
[TBL] [Abstract][Full Text] [Related]
17. Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study.
Barakat MR; Wykoff CC; Gonzalez V; Hu A; Marcus D; Zavaleta E; Ciulla TA
Ophthalmol Retina; 2021 Jan; 5(1):60-70. PubMed ID: 32829027
[TBL] [Abstract][Full Text] [Related]
18. Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry.
Bhandari S; Nguyen V; Fraser-Bell S; Mehta H; Viola F; Baudin F; Gabrielle PH; Creuzot-Garcher C; Gillies M; Barthelmes D
Ophthalmology; 2020 May; 127(5):608-615. PubMed ID: 31932092
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study.
Korobelnik JF; Holz FG; Roider J; Ogura Y; Simader C; Schmidt-Erfurth U; Lorenz K; Honda M; Vitti R; Berliner AJ; Hiemeyer F; Stemper B; Zeitz O; Sandbrink R;
Ophthalmology; 2014 Jan; 121(1):202-208. PubMed ID: 24084497
[TBL] [Abstract][Full Text] [Related]
20. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
